Adial Pharmaceuticals commences ONWARD trial of AD 04 as a therapeutic agent for the treatment of alcohol use disorder.

Adial Pharmaceuticals, Inc. announced that it has opened clinical trial sites and is recruiting trial subjects in Latvia after receiving all necessary approvals to commence the landmark ONWARD pivotal Phase III clinical trial in Latvia , including from the State Agency of Medicines of the Republic of Latvia and the Latvian Central Ethics Committee.

The ONWARD trial is investigating Adial’s lead drug candidate, AD 04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. Shortly following approval, two investigative ONWARD clinical trial sites were initiated in Latvia and commenced trial activities, and one more site is planned in Latvia.